Abstract

Several studies have demonstrated that MUC4 is involved in progression and metastasis of pancreatic cancer (PC). Here, we report that HER3/MUC4 interaction in HER2 low cells is critical in driving pancreatic tumorigenesis. Upon HER2 knockdown, we observed elevated expression of HER3 and MUC4 and their interactions, which was confirmed by immunoprecipitation and bioinformatics analyses. In paired human PC tissues, higher percentage of HER3 positivity (10/33, 30.3%; p = 0.001) was observed than HER2 (5/33, 15.1%; p = 0.031), which was further confirmed in spontaneous mice (KPC; KrasG12D; Trp53R172H/+; Pdx-Cre) tumors of different weeks. Mechanistically, increased phosphorylation of ERK and expression of PI3K and c-Myc were observed in HER2 knockdown cells, suggesting a positive role for HER3/MUC4 in HER2 low cells. Further, HER2 knockdown resulted in increased proliferation, motility and tumorigenicity of PC cells. Consistently, transient knockdown of HER3 by siRNA in HER2 knockdown cells led to decreased proliferation. These observations led us to conclude that HER3 interacts with MUC4 to promote proliferation in HER2 low PC cells. Further, deficiency of both HER2 and HER3 leads to decreased proliferation of PC cells. Hence targeting these newly identified HER3/MUC4 signals would improve the PC patients survival by intercepting MUC4 mediated oncogenic signaling.

Original languageEnglish (US)
Pages (from-to)21085-21099
Number of pages15
JournalOncotarget
Volume6
Issue number25
DOIs
StatePublished - Jan 1 2015

Fingerprint

Pancreatic Neoplasms
Phenotype
Computational Biology
Phosphatidylinositol 3-Kinases
Immunoprecipitation
Small Interfering RNA
Carcinogenesis
Phosphorylation
Neoplasm Metastasis
Survival
Neoplasms

Keywords

  • HER2
  • HER3
  • KPC model
  • MUC4
  • Pancreatic cancer

ASJC Scopus subject areas

  • Oncology

Cite this

Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells. / Lakshmanan, Imayavaramban; Seshacharyulu, Parthasarathy; Haridas, Dhanya; Rachagani, Satyanarayana; Gupta, Suprit; Joshi, Suhasini; Guda, Chittibabu; Yan, Ying; Jain, Maneesh; Ganti, Apar Kishor P; Palanimuthu Ponnusamy, Moorthy; Batra, Surinder Kumar.

In: Oncotarget, Vol. 6, No. 25, 01.01.2015, p. 21085-21099.

Research output: Contribution to journalArticle

@article{1ed57fdde3114711892a8385696a3290,
title = "Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells",
abstract = "Several studies have demonstrated that MUC4 is involved in progression and metastasis of pancreatic cancer (PC). Here, we report that HER3/MUC4 interaction in HER2 low cells is critical in driving pancreatic tumorigenesis. Upon HER2 knockdown, we observed elevated expression of HER3 and MUC4 and their interactions, which was confirmed by immunoprecipitation and bioinformatics analyses. In paired human PC tissues, higher percentage of HER3 positivity (10/33, 30.3{\%}; p = 0.001) was observed than HER2 (5/33, 15.1{\%}; p = 0.031), which was further confirmed in spontaneous mice (KPC; KrasG12D; Trp53R172H/+; Pdx-Cre) tumors of different weeks. Mechanistically, increased phosphorylation of ERK and expression of PI3K and c-Myc were observed in HER2 knockdown cells, suggesting a positive role for HER3/MUC4 in HER2 low cells. Further, HER2 knockdown resulted in increased proliferation, motility and tumorigenicity of PC cells. Consistently, transient knockdown of HER3 by siRNA in HER2 knockdown cells led to decreased proliferation. These observations led us to conclude that HER3 interacts with MUC4 to promote proliferation in HER2 low PC cells. Further, deficiency of both HER2 and HER3 leads to decreased proliferation of PC cells. Hence targeting these newly identified HER3/MUC4 signals would improve the PC patients survival by intercepting MUC4 mediated oncogenic signaling.",
keywords = "HER2, HER3, KPC model, MUC4, Pancreatic cancer",
author = "Imayavaramban Lakshmanan and Parthasarathy Seshacharyulu and Dhanya Haridas and Satyanarayana Rachagani and Suprit Gupta and Suhasini Joshi and Chittibabu Guda and Ying Yan and Maneesh Jain and Ganti, {Apar Kishor P} and {Palanimuthu Ponnusamy}, Moorthy and Batra, {Surinder Kumar}",
year = "2015",
month = "1",
day = "1",
doi = "10.18632/oncotarget.3912",
language = "English (US)",
volume = "6",
pages = "21085--21099",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "25",

}

TY - JOUR

T1 - Novel HER3/MUC4 oncogenic signaling aggravates the tumorigenic phenotypes of pancreatic cancer cells

AU - Lakshmanan, Imayavaramban

AU - Seshacharyulu, Parthasarathy

AU - Haridas, Dhanya

AU - Rachagani, Satyanarayana

AU - Gupta, Suprit

AU - Joshi, Suhasini

AU - Guda, Chittibabu

AU - Yan, Ying

AU - Jain, Maneesh

AU - Ganti, Apar Kishor P

AU - Palanimuthu Ponnusamy, Moorthy

AU - Batra, Surinder Kumar

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Several studies have demonstrated that MUC4 is involved in progression and metastasis of pancreatic cancer (PC). Here, we report that HER3/MUC4 interaction in HER2 low cells is critical in driving pancreatic tumorigenesis. Upon HER2 knockdown, we observed elevated expression of HER3 and MUC4 and their interactions, which was confirmed by immunoprecipitation and bioinformatics analyses. In paired human PC tissues, higher percentage of HER3 positivity (10/33, 30.3%; p = 0.001) was observed than HER2 (5/33, 15.1%; p = 0.031), which was further confirmed in spontaneous mice (KPC; KrasG12D; Trp53R172H/+; Pdx-Cre) tumors of different weeks. Mechanistically, increased phosphorylation of ERK and expression of PI3K and c-Myc were observed in HER2 knockdown cells, suggesting a positive role for HER3/MUC4 in HER2 low cells. Further, HER2 knockdown resulted in increased proliferation, motility and tumorigenicity of PC cells. Consistently, transient knockdown of HER3 by siRNA in HER2 knockdown cells led to decreased proliferation. These observations led us to conclude that HER3 interacts with MUC4 to promote proliferation in HER2 low PC cells. Further, deficiency of both HER2 and HER3 leads to decreased proliferation of PC cells. Hence targeting these newly identified HER3/MUC4 signals would improve the PC patients survival by intercepting MUC4 mediated oncogenic signaling.

AB - Several studies have demonstrated that MUC4 is involved in progression and metastasis of pancreatic cancer (PC). Here, we report that HER3/MUC4 interaction in HER2 low cells is critical in driving pancreatic tumorigenesis. Upon HER2 knockdown, we observed elevated expression of HER3 and MUC4 and their interactions, which was confirmed by immunoprecipitation and bioinformatics analyses. In paired human PC tissues, higher percentage of HER3 positivity (10/33, 30.3%; p = 0.001) was observed than HER2 (5/33, 15.1%; p = 0.031), which was further confirmed in spontaneous mice (KPC; KrasG12D; Trp53R172H/+; Pdx-Cre) tumors of different weeks. Mechanistically, increased phosphorylation of ERK and expression of PI3K and c-Myc were observed in HER2 knockdown cells, suggesting a positive role for HER3/MUC4 in HER2 low cells. Further, HER2 knockdown resulted in increased proliferation, motility and tumorigenicity of PC cells. Consistently, transient knockdown of HER3 by siRNA in HER2 knockdown cells led to decreased proliferation. These observations led us to conclude that HER3 interacts with MUC4 to promote proliferation in HER2 low PC cells. Further, deficiency of both HER2 and HER3 leads to decreased proliferation of PC cells. Hence targeting these newly identified HER3/MUC4 signals would improve the PC patients survival by intercepting MUC4 mediated oncogenic signaling.

KW - HER2

KW - HER3

KW - KPC model

KW - MUC4

KW - Pancreatic cancer

UR - http://www.scopus.com/inward/record.url?scp=84940774311&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84940774311&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.3912

DO - 10.18632/oncotarget.3912

M3 - Article

C2 - 26035354

AN - SCOPUS:84940774311

VL - 6

SP - 21085

EP - 21099

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 25

ER -